Monitoring APOBEC3A Protein Levels in Human Cancer Cells

Overview

Journal Methods Cell Biol

Specialty Cell Biology

Date 2024 Feb 15

PMID 38359985

Authors

Alexandra Dananberg

John Maciejowski

Affiliations

Soon will be listed here.

Abstract

The APOBEC3 family of cytosine deaminases, which target single-stranded DNA and RNA of viruses and retroelements as part of the innate immune defense, generate mutations in many human cancers. Although the APOBEC3A paralog is a major endogenous source of these mutations, low APOBEC3A mRNA levels and protein abundance have hampered functional characterization. Extensive homology across APOBEC3 paralogs have further challenged the development of specific detection reagents. Here, we describe the isolation and use of monoclonal antibodies with specificity for APOBEC3A and the APOBEC3A/APOBEC3B/APOBEC3G proteins. We provide protocols and technical advice for detection and measurement of APOBEC3A protein across human cancer cell lines using standard immunoblotting and immunofluorescence protocols.

References

Kanu N, Cerone M, Goh G, Zalmas L, Bartkova J, Dietzen M . DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome Biol. 2016; 17(1):185. PMC: 5025597. DOI: 10.1186/s13059-016-1042-9. View

Nik-Zainal S, Alexandrov L, Wedge D, Van Loo P, Greenman C, Raine K . Mutational processes molding the genomes of 21 breast cancers. Cell. 2012; 149(5):979-93. PMC: 3414841. DOI: 10.1016/j.cell.2012.04.024. View

Mussil B, Suspene R, Aynaud M, Gauvrit A, Vartanian J, Wain-Hobson S . Human APOBEC3A isoforms translocate to the nucleus and induce DNA double strand breaks leading to cell stress and death. PLoS One. 2013; 8(8):e73641. PMC: 3748023. DOI: 10.1371/journal.pone.0073641. View

Stavrou S, Ross S . APOBEC3 Proteins in Viral Immunity. J Immunol. 2015; 195(10):4565-70. PMC: 4638160. DOI: 10.4049/jimmunol.1501504. View

Munk C, Willemsen A, Bravo I . An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evol Biol. 2012; 12:71. PMC: 3495650. DOI: 10.1186/1471-2148-12-71. View

Alexandrov L, Kim J, Haradhvala N, Huang M, Ng A, Wu Y . The repertoire of mutational signatures in human cancer. Nature. 2020; 578(7793):94-101. PMC: 7054213. DOI: 10.1038/s41586-020-1943-3. View

Thielen B, McNevin J, McElrath M, Vander Stoep Hunt B, Klein K, Lingappa J . Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem. 2010; 285(36):27753-66. PMC: 2934643. DOI: 10.1074/jbc.M110.102822. View

Lackey L, Law E, Brown W, Harris R . Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle. 2013; 12(5):762-72. PMC: 3610724. DOI: 10.4161/cc.23713. View

Burns M, Lackey L, Carpenter M, Rathore A, Land A, Leonard B . APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 2013; 494(7437):366-70. PMC: 3907282. DOI: 10.1038/nature11881. View

10.

Niocel M, Appourchaux R, Nguyen X, Delpeuch M, Cimarelli A . The DNA damage induced by the Cytosine Deaminase APOBEC3A Leads to the production of ROS. Sci Rep. 2019; 9(1):4714. PMC: 6423136. DOI: 10.1038/s41598-019-40941-8. View

11.

Buisson R, Langenbucher A, Bowen D, Kwan E, Benes C, Zou L . Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features. Science. 2019; 364(6447). PMC: 6731024. DOI: 10.1126/science.aaw2872. View

12.

Degasperi A, Zou X, Amarante T, Martinez-Martinez A, Koh G, Dias J . Substitution mutational signatures in whole-genome-sequenced cancers in the UK population. Science. 2022; 376(6591. PMC: 7613262. DOI: 10.1126/science.abl9283. View

13.

Jalili P, Bowen D, Langenbucher A, Park S, Aguirre K, Corcoran R . Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots. Nat Commun. 2020; 11(1):2971. PMC: 7293259. DOI: 10.1038/s41467-020-16802-8. View

14.

Roberts S, Lawrence M, Klimczak L, Grimm S, Fargo D, Stojanov P . An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013; 45(9):970-6. PMC: 3789062. DOI: 10.1038/ng.2702. View

15.

Roberts S, Sterling J, Thompson C, Harris S, Mav D, Shah R . Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol Cell. 2012; 46(4):424-35. PMC: 3361558. DOI: 10.1016/j.molcel.2012.03.030. View

16.

Landry S, Narvaiza I, Linfesty D, Weitzman M . APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep. 2011; 12(5):444-50. PMC: 3090015. DOI: 10.1038/embor.2011.46. View

17.

DeWeerd R, Nemeth E, Poti A, Petryk N, Chen C, Hyrien O . Prospectively defined patterns of APOBEC3A mutagenesis are prevalent in human cancers. Cell Rep. 2022; 38(12):110555. PMC: 9283007. DOI: 10.1016/j.celrep.2022.110555. View

18.

Harris R, Petersen-Mahrt S, Neuberger M . RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell. 2002; 10(5):1247-53. DOI: 10.1016/s1097-2765(02)00742-6. View

19.

Carpenter M, Temiz N, Ibrahim M, Jarvis M, Brown M, Argyris P . Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer. PLoS Genet. 2023; 19(11):e1011043. PMC: 10715669. DOI: 10.1371/journal.pgen.1011043. View

20.

Law E, Sieuwerts A, LaPara K, Leonard B, Starrett G, Molan A . The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Sci Adv. 2016; 2(10):e1601737. PMC: 5055383. DOI: 10.1126/sciadv.1601737. View